FGFR1 and colorectal cancer: For example, a Phase I clinical trial for FGFR1–3 inhibitor AZD4547 for 30 solid cancer patients with FGFR mutations, amplifications, or fusions included three colorectal cancer patients, but no data on their sensitivity to AZD4547 were available [11].